

# Howard H Feldman

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6825664/howard-h-feldman-publications-by-year.pdf>  
**Version:** 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

147 papers	38,002 citations	61 h-index	164 g-index
164 ext. papers	44,488 ext. citations	8 avg, IF	6.43 L-index

#	Paper	IF	Citations
147	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease.. <i>Nature Communications</i> , <b>2022</b> , 13, 1495	17.4	0
146	A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure. <i>Nature Communications</i> , <b>2021</b> , 12, 7065	17.4	2
145	Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab.. <i>Canadian Geriatrics Journal</i> , <b>2021</b> , 24, 373-378	2.8	0
144	Value-Generating Exploratory Trials in Neurodegenerative Dementias. <i>Neurology</i> , <b>2021</b> , 96, 944-954	6.5	5
143	Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	4
142	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology</i> , <i>The</i> , <b>2021</b> , 20, 484-496	24.1	86
141	Sleep and its regulation: An emerging pathogenic and treatment frontier in Alzheimer's disease. <i>Progress in Neurobiology</i> , <b>2021</b> , 197, 101902	10.9	11
140	Impact of potential modifications to Alzheimer's disease clinical trials in response to disruption by COVID-19: a simulation study.. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 201	9	1
139	Premature termination codon readthrough upregulates progranulin expression and improves lysosomal function in preclinical models of GRN deficiency. <i>Molecular Neurodegeneration</i> , <b>2020</b> , 15, 21	19	8
138	World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, 1078-1094	1.2	109
137	Applying the Alzheimer Disease ATN Diagnostic Framework in Atypical Dementia. <i>Alzheimer Disease and Associated Disorders</i> , <b>2020</b> , 34, 357-359	2.5	1
136	New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, 131-143	1.2	24
135	Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measures. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2020</b> , 6, e12071	6	3
134	The "rights" of precision drug development for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 76	9	93
133	A randomized clinical trial to evaluate home-based assessment of people over 75 years old. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 615-624	1.2	4
132	Cognitive heterogeneity in probable Alzheimer disease: Clinical and neuropathologic features. <i>Neurology</i> , <b>2019</b> , 93, e778-e790	6.5	16
131	The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. <i>Canadian Journal of Neurological Sciences</i> , <b>2019</b> , 46, 499-511	1	28

130	Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical Trial. <i>JAMA Neurology</i> , <b>2019</b> , 76, 1330-1339	17.2	14
129	Delayed daily activity and reduced NREM slow-wave power in the APPswe/PS1dE9 mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2019</b> , 78, 74-86	5.6	16
128	Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease. <i>Acta Neuropathologica</i> , <b>2019</b> , 137, 209-226	14.3	54
127	Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 67, 707-713	4.3	7
126	Therapeutic trial design for frontotemporal dementia and related disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 412-423	5.5	16
125	16-Year Survival of the Canadian Collaborative Cohort of Related Dementias. <i>Canadian Journal of Neurological Sciences</i> , <b>2018</b> , 45, 367-374	1	1
124	Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 1397-1405	1.2	5
123	Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY). <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 102	9	13
122	Gray matter changes in asymptomatic and mutation carriers. <i>NeuroImage: Clinical</i> , <b>2018</b> , 18, 591-598	5.3	16
121	The 2002 NIMH Provisional Diagnostic Criteria for Depression of Alzheimer's Disease (PDC-dAD): Gauging their Validity over a Decade Later. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 58, 449-462	4.3	13
120	Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. <i>Neurology</i> , <b>2017</b> , 89, 88-100	6.5	1691
119	Neurobehavioral characterization of adult-onset Alexander disease: A family study. <i>Neurology: Clinical Practice</i> , <b>2017</b> , 7, 425-429	1.7	3
118	The Canadian dementia challenge: Ensuring optimal care and services for those at risk or with dementia throughout the country. <i>Canadian Journal of Public Health</i> , <b>2017</b> , 108, e95-e97	3.2	11
117	Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. <i>Lancet, The</i> , <b>2016</b> , 388, 2873-2884	40	214
116	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , <b>2016</b> , 12, 292-323	1.2	832
115	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology, The</i> , <b>2016</b> , 15, 455-532	24.1	921
114	Effect of diesel exhaust inhalation on blood markers of inflammation and neurotoxicity: a controlled, blinded crossover study. <i>Inhalation Toxicology</i> , <b>2016</b> , 28, 145-53	2.7	27
113	Periventricular hyperintensities are associated with elevated cerebral amyloid. <i>Neurology</i> , <b>2016</b> , 86, 535-543	4.3	60

112	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. <i>Neurology</i> , <b>2016</b> , 87, 539-47	6.5	710
111	F5-03-02: Biomarkers are Useful in Tertiary Care Clinical Decision-Making <b>2016</b> , 12, P370-P370		
110	Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial. <i>JAMA Neurology</i> , <b>2015</b> , 72, 1324-33	17.2	134
109	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , <b>2014</b> , 13, 614-29	24.1	1985
108	Evaluation of late-onset Alzheimer disease genetic susceptibility risks in a Canadian population. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 936.e5-12	5.6	37
107	IC-P-108: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODRAMAL AD POPULATION <b>2014</b> , 10, P60-P61		
106	P4-038: CREATION OF THE CANADIAN CONSORTIUM FOR NEURODEGENERATION IN AGING <b>2014</b> , 10, P796-P796		
105	P2-202: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODRAMAL AD POPULATION <b>2014</b> , 10, P546-P547		
104	Alzheimer's disease research and development: a call for a new research roadmap. <i>Annals of the New York Academy of Sciences</i> , <b>2014</b> , 1313, 1-16	6.5	24
103	Early neuropsychological characteristics of progranulin mutation carriers. <i>Journal of the International Neuropsychological Society</i> , <b>2014</b> , 20, 694-703	3.1	15
102	Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. <i>Alzheimer's Research and Therapy</i> , <b>2013</b> , 5, S2	9	81
101	F50302: Perspective from the clinical research and manufacturing communities <b>2013</b> , 9, P826-P826		
100	The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 189-98	1.2	42
99	Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 176-88	1.2	45
98	Pharmacodynamics of selective inhibition of $\beta$ -secretase by avagacestat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2013</b> , 344, 686-95	4.7	52
97	Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 123-131.e1	1.2	82
96	A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. <i>Progress in Neurobiology</i> , <b>2013</b> , 110, 114-23	10.9	19
95	Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. <i>Neurology</i> , <b>2013</b> , 81, 1322-31	6.5	45

94	The Diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease: Recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease. <i>Focus (American Psychiatric Publishing)</i> , <b>2013</b> , 11, 96-106	1.1	36
93	Synaptic dysfunction in progranulin-deficient mice. <i>Neurobiology of Disease</i> , <b>2012</b> , 45, 711-22	7.5	119
92	Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 1203-14	5.6	278
91	Safety and tolerability of the $\beta$ -secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. <i>Archives of Neurology</i> , <b>2012</b> , 69, 1430-40		266
90	Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. <i>Brain</i> , <b>2012</b> , 135, 709-22	11.2	172
89	rs5848 polymorphism and serum progranulin level. <i>Journal of the Neurological Sciences</i> , <b>2011</b> , 300, 28-32	3.2	64
88	Prevention trials in Alzheimer's disease: an EU-US task force report. <i>Progress in Neurobiology</i> , <b>2011</b> , 95, 594-600	10.9	52
87	Global issues in drug development for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2011</b> , 7, 197-207	1.2	12
86	The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2011</b> , 7, 270-9	1.2	5630
85	Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. <i>Alzheimer's and Dementia</i> , <b>2011</b> , 7, 367-85	1.2	364
84	New lexicon and criteria for the diagnosis of Alzheimer's disease Authors' reply. <i>Lancet Neurology</i> , <b>2011</b> , 10, 300-301	24.1	6
83	Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. <i>Neuron</i> , <b>2011</b> , 72, 245-56	13.9	3267
82	Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. <i>Archives of Neurology</i> , <b>2011</b> , 68, 488-97		93
81	Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2011</b> , 82, 196-203	5.5	146
80	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. <i>Nature Genetics</i> , <b>2010</b> , 42, 234-9	36.3	361
79	The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. <i>Archives of Neurology</i> , <b>2010</b> , 67, 161-70		143
78	An exploration of cognitive subgroups in Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , <b>2010</b> , 16, 233-43	3.1	24
77	Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2010</b> , 30, 161-78	2.6	570

76	Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study. <i>Journal of the Neurological Sciences</i> , <b>2010</b> , 288, 142-6	3.2	21
75	Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. <i>Neuron</i> , <b>2010</b> , 68, 654-67	13.9	368
74	Dependence as a unifying construct in defining Alzheimer's disease severity. <i>Alzheimer's and Dementia</i> , <b>2010</b> , 6, 482-93	1.2	43
73	Differentiating the frontal variant of Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , <b>2010</b> , 25, 732-8	3.9	58
72	Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. <i>Depression and Anxiety</i> , <b>2010</b> , 27, 417-25	8.4	126
71	Predicting response to acetylcholinesterase inhibitor treatment in Alzheimer disease: has the time come?. <i>Nature Reviews Neurology</i> , <b>2009</b> , 5, 128-9	15	4
70	Minimizing misdiagnosis: psychometric criteria for possible or probable memory impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2009</b> , 27, 439-50	2.6	44
69	Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2009</b> , 28, 244-51	2.6	36
68	Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. <i>International Journal of Geriatric Psychiatry</i> , <b>2009</b> , 24, 479-88	3.9	50
67	Assessing the validity of deriving clinical dementia rating (CDR) global scores from independently-obtained functional rating scale (FRS) scores in vascular dementia with and without Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , <b>2009</b> , 24, 1174-6	3.9	4
66	Therapeutic potential of statins in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , <b>2009</b> , 283, 230-4	3.2	87
65	Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach. <i>Gender Medicine</i> , <b>2009</b> , 6, 345-55		12
64	Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil. <i>Alzheimer Disease and Associated Disorders</i> , <b>2009</b> , 23, 357-64	2.5	18
63	Revised research diagnostic criteria for Alzheimer's disease. <i>Lancet Neurology</i> , <b>2008</b> , 7, 668-70	24.1	18
62	Diagnosis and treatment of dementia: 2. Diagnosis. <i>Cmaj</i> , <b>2008</b> , 178, 825-36	3.5	142
61	Neuropsychiatric symptom clusters and functional disability in cognitively-impaired-not-demented individuals. <i>American Journal of Geriatric Psychiatry</i> , <b>2008</b> , 16, 136-44	6.5	19
60	The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. <i>Alzheimer's and Dementia</i> , <b>2008</b> , 4, 145-53	1.2	44
59	Pharmacological treatment in moderate-to-severe Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2008</b> , 9, 2575-82	4	17

58	Transition from cognitively impaired not demented to Alzheimer's disease: an analysis of changes in functional abilities in a dementia clinic cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2008</b> , 25, 483-90	2.6	21
57	Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. <i>Archives of Neurology</i> , <b>2008</b> , 65, 45-53		362
56	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. <i>Human Molecular Genetics</i> , <b>2008</b> , 17, 3631-42	5.6	242
55	Cognitive impairment no dementia - neuropsychological and neuroimaging characterization of an amnesic subgroup. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2008</b> , 25, 238-47	2.6	15
54	Potential for misclassification of mild cognitive impairment: a study of memory scores on the Wechsler Memory Scale-III in healthy older adults. <i>Journal of the International Neuropsychological Society</i> , <b>2008</b> , 14, 463-78	3.1	119
53	Superficial siderosis: a potential diagnostic marker of cerebral amyloid angiopathy in Alzheimer disease. <i>Stroke</i> , <b>2008</b> , 39, 2894-7	6.7	64
52	Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> , <b>2008</b> , 18, 289-98 <sup>9</sup>		43
51	Early identification of Alzheimer's disease: what have we learned from mild cognitive impairment?. <i>CNS Spectrums</i> , <b>2008</b> , 13, 4-7	1.8	2
50	Clinical presentation of prodromal frontotemporal dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , <b>2007</b> , 22, 456-67	2.5	16
49	Disease progression in vascular cognitive impairment: cognitive, functional and behavioural outcomes in the Consortium to Investigate Vascular Impairment of Cognition (CIVIC) cohort study. <i>Journal of the Neurological Sciences</i> , <b>2007</b> , 252, 106-12	3.2	28
48	Clinical phenotypes of Cerebral Amyloid Angiopathy. <i>Journal of the Neurological Sciences</i> , <b>2007</b> , 257, 23-30	3.2	80
47	Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. <i>Lancet Neurology</i> , <b>2007</b> , 6, 501-12	24.1	260
46	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. <i>Lancet Neurology</i> , <b>2007</b> , 6, 734-46	24.1	3067
45	Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. <i>Lancet Neurology</i> , <b>2007</b> , 6, 857-68	24.1	174
44	Atlas of Alzheimer's Disease <b>2007</b> ,		6
43	Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2007</b> , 78, 1056-63	5.5	54
42	Primary prevention and delay of onset of AD/dementia. <i>Canadian Journal of Neurological Sciences</i> , <b>2007</b> , 34 Suppl 1, S84-9	1	12
41	Neuropsychological testing and assessment for dementia. <i>Alzheimer's and Dementia</i> , <b>2007</b> , 3, 299-317	1.2	84



40	Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease. <i>BMC Neurology</i> , <b>2006</b> , 6, 32	3.1	6
39	A family with tau-negative frontotemporal dementia and neuronal intranuclear inclusions linked to chromosome 17. <i>Brain</i> , <b>2006</b> , 129, 853-67	11.2	96
38	The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. <i>Brain</i> , <b>2006</b> , 129, 3081-90	11.2	259
37	Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. <i>Human Molecular Genetics</i> , <b>2006</b> , 15, 2988-3001	5.6	463
36	Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , <b>2006</b> , 20, 732-55	4.6	124
35	Outcomes of cognitively impaired not demented at 2 years in the Canadian Cohort Study of Cognitive Impairment and Related Dementias. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2006</b> , 22, 413-20	3.6	41
34	Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. <i>Science</i> , <b>2006</b> , 314, 130-3	33.3	4289
33	Mild cognitive impairment. <i>Lancet, The</i> , <b>2006</b> , 367, 1262-70	4.0	1703
32	Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: what have we learned?. <i>Alzheimer's and Dementia</i> , <b>2006</b> , 2, 220-33	1.2	22
31	Clinical and radiographic subtypes of vascular cognitive impairment in a clinic-based cohort study. <i>Journal of the Neurological Sciences</i> , <b>2006</b> , 240, 7-14	3.2	30
30	Drug Treatment: Cholinesterase Inhibitors <b>2006</b> , 131-149		1
29	Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: a conceptual summary. <i>Canadian Journal of Neurological Sciences</i> , <b>2006</b> , 33, 6-26	1	14
28	Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. <i>Alzheimer Disease and Associated Disorders</i> , <b>2006</b> , 20, 263-8	2.5	55
27	Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. <i>Nature</i> , <b>2006</b> , 442, 916-9	50.4	1549
26	Mild Cognitive Impairment. <i>American Journal of Geriatric Psychiatry</i> , <b>2005</b> , 13, 645-655	6.5	81
25	Neuropsychological subgroups of cognitively-impaired-not-demented (CIND) individuals: delineation, reliability, and predictive validity. <i>Journal of Clinical and Experimental Neuropsychology</i> , <b>2005</b> , 27, 164-88	2.1	10
24	Ubiquitin immunohistochemistry suggests classic motor neuron disease, motor neuron disease with dementia, and frontotemporal dementia of the motor neuron disease type represent a clinicopathologic spectrum. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2005</b> , 64, 730-9	3.1	114
23	Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. <i>Alzheimer Disease and Associated Disorders</i> , <b>2005</b> , 19, 29-36	2.5	80



22	Cholesterol in Alzheimer's disease. <i>Lancet Neurology, The</i> , <b>2005</b> , 4, 841-52	24.1	251
21	Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. <i>International Journal of Geriatric Psychiatry</i> , <b>2005</b> , 20, 559-69	3.9	94
20	Mild cognitive impairment. <i>American Journal of Geriatric Psychiatry</i> , <b>2005</b> , 13, 645-55	6.5	62
19	Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. <i>Cmaj</i> , <b>2004</b> , 171, 863-7	3.5	117
18	Neuronal intranuclear inclusions distinguish familial FTD-MND type from sporadic cases. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2004</b> , 17, 333-6	2.6	19
17	Neuropsychological characterization of cognitively-impaired-not-demented (CIND) individuals: clinical comparison data. <i>Clinical Neuropsychologist</i> , <b>2004</b> , 18, 208-28	4.4	5
16	Dementia with Lewy bodies. <i>Lancet Neurology, The</i> , <b>2004</b> , 3, 19-28	24.1	560
15	Extrapyramidal features in patients with motor neuron disease and dementia; a clinicopathological correlative study. <i>Acta Neuropathologica</i> , <b>2004</b> , 107, 336-40	14.3	19
14	What are the treatment options for patients with severe Alzheimer's disease?. <i>CNS Drugs</i> , <b>2004</b> , 18, 575-83	20	
13	Emerging therapies for vascular dementia and vascular cognitive impairment. <i>Stroke</i> , <b>2004</b> , 35, 1010-7	6.7	173
12	Fatal familial insomnia: the first account in a family of Chinese descent. <i>Archives of Neurology</i> , <b>2004</b> , 61, 122-5		24
11	The Consortium to Investigate Vascular Impairment of Cognition: methods and first findings. <i>Canadian Journal of Neurological Sciences</i> , <b>2003</b> , 30, 237-43	1	78
10	The relationship between extramotor ubiquitin-immunoreactive neuronal inclusions and dementia in motor neuron disease. <i>Acta Neuropathologica</i> , <b>2003</b> , 105, 98-102	14.3	43
9	Neuronal intranuclear inclusions distinguish familial FTD-MND type from sporadic cases. <i>Acta Neuropathologica</i> , <b>2003</b> , 105, 543-8	14.3	33
8	Treatment of Alzheimer's disease: current status and new perspectives. <i>Lancet Neurology, The</i> , <b>2003</b> , 2, 539-47	24.1	590
7	Epidemiology and genetics of frontotemporal dementia/Pick's disease. <i>Annals of Neurology</i> , <b>2003</b> , 54 Suppl 5, S29-31	9.4	99
6	Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. <i>Journal of the American Geriatrics Society</i> , <b>2003</b> , 51, 737-44	5.6	161
5	Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. <i>International Psychogeriatrics</i> , <b>2002</b> , 14, 389-404	3.4	177

4	A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease. <i>Canadian Journal of Neurological Sciences</i> , <b>1997</b> , 24, 140-5	1	40
3	Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. <i>Nature Medicine</i> , <b>1996</b> , 2, 1230-5	50.5	152
2	Canadian guidelines for the development of antidementia therapies: a conceptual summary. <i>Canadian Journal of Neurological Sciences</i> , <b>1995</b> , 22, 62-71	1	36
1	The Dementias: An Overview116-119		